Effect of Daily Glucomannan in Overweight Patients

Phase 4

• Conditions: Overweight; Obesity
• Interventions: Dietary Supplement: Glucomannan; Dietary Supplement: Placebo

• Registration Number: NCT01485718
• Lead Sponsor: ProMedica Health System

Brief Summary

Glucomannan is a dietary supplement that has been marketed for weight loss. There is some research that supports this claim but more research is necessary. This is research study is being conducted to determine if the dietary supplement glucomannan is effective for weight loss in adults greater than 18 years of age who are overweight.

Participants will be randomized in a 1:1 manner (like the flip of a coin) to receive either glucomannan 575 milligrams, 2 capsules three times daily or placebo, 2 capsules three times daily. The study will last for 12 weeks.

At the start of the study participants will be asked questions about current medications and diet/exercise regimen, a weight and height will be obtained, and they will be given a one-month's supply of study supplement. An investigator will call each participant after they have been taking the supplement for 2 weeks to ensure that the participant is tolerating the supplement and answer any questions. Throughout the study, participants will be required to follow-up with investigators in the office every 4 weeks (a total of 3 follow-up appointments). Every 4 weeks, the investigators will weigh participants, count the leftover capsules from the previous month, and ask about any adverse effects you may be experiencing. At the conclusion of the study, a final weight will be compared with the baseline weight to determine if the medication had an effect on weight loss.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-10
• Study First Submitted: 2011-11-26
• Status Verified: 2011-12
• Study First Submitted QC: 2011-12-02
• Study First Posted: 2011-12-05
• Last Update Submitted: 2011-12-09
• Last Update Posted: 2011-12-13
• Primary Completion: 2012-03
• Study Completion: 2012-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Patients ≥18 years old
• Overweight (BMI ≥ 25 kg/m2)

Exclusion Criteria

• Pregnant or nursing women

• Women of childbearing age will be excluded unless they are on some form of contraception

• Participation in any other formal or informal weight reduction program

  1. Currently enrolled in another weight loss study

  2. Currently enrolled in a weight loss program

  3. Active attempt to lose weight with diet and/or exercise within the last month

  4. Currently on one of the following medications known to cause weight loss:

     • Alli/Xenical(orlistat)
     • Adipex-P (phentermine)
     • Bontril (phendimetrazine)
     • Dexoxyn (methamphetamine)
     • Didrex (benzphetamine)
     • Tenuate (diethylpropion)
     • Meridia (sibutramine)
     • Byetta (exenatide) or Victoza (liraglutide)
     • Stimulants

• Recently (within the last three months) started on any medication that may cause weight gain

• A diagnosis of heart failure

• Structural abnormalities of the esophagus or gut

• Previous GI surgery for weight reduction

• Inflammatory bowel or irritable bowel disease

• A life expectancy of <6 months

• Allergy to glucomannan or any component of the placebo

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Glucomannan	Glucomannan	Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day.
Placebo	Placebo	Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.

Primary Outcome Measures

Name	Time	Method
Weight	12 weeks	The primary outcome is the difference between weight at 12 weeks and the baseline weight.

Secondary Outcome Measures

Name	Time	Method
Side Effects	Assessed at 2, 4, 8, and 12 week intervals	Patient reported side effects assessed at each patient visit. Specifically side effects related to gastrointestinal function.

Trial Locations

Locations (1)

W.W. Knight Family Practice Center; 🇺🇸 Toledo, Ohio, United States